Daniel C. Sévin

Daniel C. Sévin

Auto-generated profile, based on publicly available information

Daniel C. Sévin

Cellzome a GSK company, 69115 Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Molecular Systems Biology
Verified
Journal Article
Open access
SWSander Wuyts
Sander Wuyts
RARenato Alves
Renato Alves
MZMaria Zimmermann‐Kogadeeva
Maria Zimmermann‐Kogadeeva
SNSuguru Nishijima
Suguru Nishijima
SBSonja Blasche
Sonja Blasche
PBPeer Bork
Peer Bork
Multi‐omics analyses are used in microbiome studies to understand molecular changes in microbial communities exposed to different conditions. However, it is not always clear how much each omics data type contributes to our understanding and whether they are concordant with each other. Here, we map the molecular response of a synthetic community of 32 human gut bacteria to three non‐antibiotic drugs by using five omics layers (16S rRNA gene profiling, metagenomics, metatranscriptomics, metaproteomics and metabolomics). We find that all the omics methods with species resolution are highly consistent in estimating relative species abundances. Furthermore, different omics methods complement each other for capturing functional changes. For example, while nearly all the omics data types captured that the antipsychotic drug chlorpromazine selectively inhibits Bacteroidota representatives in the community, the metatranscriptome and metaproteome suggested that the drug induces stress responses related to protein quality control. Metabolomics revealed a decrease in oligosaccharide uptake, likely caused by Bacteroidota depletion. Our study highlights how multi‐omics datasets can be utilized to reveal complex molecular responses to external perturbations in microbial communities.

1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ARAnna Rutkowska
Anna Rutkowska
HEH. Christian Eberl
H. Christian Eberl
TWThilo Werner
Thilo Werner
MHMarco L. Hennrich
Marco L. Hennrich
DSDaniel C. Sévin
Daniel C. Sévin
GBGiovanna Bergamini
Giovanna Bergamini
An in-depth multiomic molecular characterization of PARP inhibitors revealed a distinct poly-pharmacology of niraparib (Zejula) mediated by its interaction with lanosterol synthase (LSS), which is not observed with other PARP inhibitors. Niraparib, in a similar way to the LSS inhibitor Ro-48-8071, induced activation of the 24,25-epoxysterol shunt pathway, which is a regulatory signaling branch of the cholesterol biosynthesis pathway. Interestingly, the combination of an LSS inhibitor with a PARP inhibitor that does not bind to LSS, such as olaparib, had an additive effect on killing cancer cells to levels comparable with niraparib as a single agent. In addition, the combination of PARP inhibitors and statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an enzyme catalyzing the rate-limiting step in the mevalonate pathway, had a synergistic effect on tumor cell killing in cell lines and patient-derived ovarian tumor organoids. These observations suggest that concomitant inhibition of the cholesterol biosynthesis pathway and PARP activity might result in stronger efficacy of these inhibitors against tumor types highly dependent on cholesterol metabolism. Significance: The presented data indicate, to our knowledge, for the first time, the potential benefit of concomitant modulation of cholesterol biosynthesis pathway and PARP inhibition and highlight the need for further investigation to assess its translational relevance.

18 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJames L. Cairns
James L. Cairns
JHJohanna Huber
Johanna Huber
ALAndrea Lewen
Andrea Lewen
JJJessica Jung
Jessica Jung
SMStefan J. Maurer
Stefan J. Maurer
CHCarsten Hopf
Carsten Hopf
Single-cell MALDI mass spectrometry imaging (MSI) of lipids and metabolites >200 Da has recently come to the forefront of biomedical research and chemical biology, but fast metabolome-preserving methods without paraformaldehyde fixation for analysis of low mass, hydrophilic metabolites (<200 Da) in large cell populations are lacking. Introducing giant unilamellar vesicles (GUVs) as MSI ground truth for cell-sized objects and Monte Carlo reference-based consensus clustering for data-dependent identification of cell subpopulations. The PRISM-MS ( PR escan I maging for S mall M olecule - M ass S pectrometry) dual-scan MSI workflow is presented, enabling space-efficient and therefore faster lipid analysis in single GUVs and cells. Beyond lipids, PRISM-MS enables MSI and on-cell MS2-based identification of low-mass metabolites like amino acids or Krebs cycle intermediates involved in stimulus-dependent cell activation. The utility of PRISM-MS is demonstrated through the characterization of complex metabolome changes in lipopolysaccharide (LPS)-stimulated microglial cells and human-induced pluripotent stem cell-derived microglia. Translation of single cell results to endogenous microglia in organotypic hippocampal slice cultures indicates that LPS-activation involves changes of the itaconate-to-taurine ratio and alterations in neuron-to-glia glutamine-glutamate shuttling. The data suggests that PRISM-MS could serve as a standard method in single cell metabolomics, given its capability to characterize larger cell populations and low-mass metabolites.

26 March 2025
Verified
Other
Open access
ARAnna Rutkowska
Anna Rutkowska
HEH. Christian Eberl
H. Christian Eberl
TWThilo Werner
Thilo Werner
MHMarco L. Hennrich
Marco L. Hennrich
DSDaniel C. Sévin
Daniel C. Sévin
GBGiovanna Bergamini
Giovanna Bergamini
Table S2 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation

26 March 2025
Verified
Other
Open access
ARAnna Rutkowska
Anna Rutkowska
HEH. Christian Eberl
H. Christian Eberl
TWThilo Werner
Thilo Werner
MHMarco L. Hennrich
Marco L. Hennrich
DSDaniel C. Sévin
Daniel C. Sévin
GBGiovanna Bergamini
Giovanna Bergamini
Niraparib specific modulation of cholesterol biosynthesis pathway in cancer cell lines

26 March 2025
Verified
Other
Open access
ARAnna Rutkowska
Anna Rutkowska
HEH. Christian Eberl
H. Christian Eberl
TWThilo Werner
Thilo Werner
MHMarco L. Hennrich
Marco L. Hennrich
DSDaniel C. Sévin
Daniel C. Sévin
GBGiovanna Bergamini
Giovanna Bergamini
Niraparib matrix (affinity enrichment chemoproteomics)